@article {2004, title = {Analysis of Deferred Blood Donor Candidates at Dr. Sardjito Hospital, Yogyakarta, Indonesia}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {April 2023}, pages = {333-337}, type = {Research Article}, chapter = {333}, abstract = {

Background: The selection of blood donor candidates contributes to the safety of donors and donor recipients. An understanding of the characteristics, demographic characteristics, and types of potential blood donors are essential to obtain an accurate picture of the donor donors, thereby guiding recruitment strategies and providing benchmarks to assess the success of blood donation. Objective: This scientific work aims to analyze the deferred blood donor candidates annually based on the required blood donor characteristics at the Blood Transfusion Unit (BTU) of Dr. Sardjito Hospital, Yogyakarta, Indonesia, from 2017 to 2019. Method: This observational analytic study applied a retrospective design and was conducted at Dr. Sardjito Hospital, Yogyakarta. The data were collected from the donor registration information system and database in the blood request system for the 2017-2019 period. The statistical analysis was conducted using the Chi-Square test in the SPSS version 22. Results: The deferred blood donor candidates in 2017-2019 amounted to 618 (0.82\%) out of 75,067 total blood donors, most of whom were female, reaching an annual percentage of 50.7\% in 2017, 50.9\% in 2018, and 59.1\% in 2019. The age range of both male and female deferred blood donor candidates was 17-30 years. The Hb levels of \< 12.5 g/dL were mostly found in female blood donors, reaching a peak of 82.4\% in 2017, 83.9\% in 2018, and 85.4.6\% in 2019. Voluntary blood donors accounted for 94.7\% (in 2017), 98.6\% (in 2018), and 100\% (in 2019) of the female deferred blood donor candidates. All analytical tests resulted in a p-value of \< 0.0001. Most of the deferred blood donor candidates had blood type O with a p = 0.026. The most common cause of deferral was high or low Hb levels in female blood donors with an age range of 17-30 years. Conclusions: The deferred blood donor candidates in 2017-2019 amounted to 618 (0.82\%) out of 75,067 total blood donors, most of whom were female with the most common deferral reason of Hb levels \< 12.5 g/dL in the age range of 17-30 years.

}, keywords = {Donors rejected, Hemoglobin., Transfusion}, doi = {10.5530/pj.2023.15.50}, author = {Teguh Triyono and Tsaniatul Afifah and Usi Sukorini} } @article {1985, title = {Effect of Platelet Concentrates (PCs) Leucodepletion on the Activation and Efficacy of Platelet Transfusion}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {March 2023}, pages = {223-227}, type = {Research Article}, chapter = {223}, abstract = {

Platelet concentrates (PCs) are blood components transfused in thrombocytopenic patients, including patients with blood malignancies. PCs contain leukocytes, which can pose potential side effects and activate platelets, reducing the efficacy of platelet transfusion. The leucodepletion process can be carried out by filtration to reduce the leukocyte count. This study aims to determine the difference between the CD62P expression of nonleucodepleted and leucodepleted PCs and to determine the difference between the Corrected Count Increment (CCI) of patients transfused with nonleucodepleted and leucodepleted PCs. This analytic observational study with a cross-sectional design was carried out on PCs obtained from platelet-rich plasma (PRP-PC). PCs were transfused into 48 blood malignancy patients, Yogyakarta, consisting of two groups i.e the group transfused with nonleucodepleted PCs (24 patients) and the group transfused with leucodepleted PCs (24 patients). CD62P expression in PCs was measured by flow cytometry method, and the CCI of the patients was calculated based on the CCI formula. The difference between the median CD62P expression and CCI of the two groups was analyzed using the Mann- Whitney Test with a significance of p\<0.05. The median CD62P expression of the nonleucodepleted and leucodepleted groups were 34.4\% (16.8{\textendash}94.4\%) and 21.7\% (6.2{\textendash}34.0\%), respectively. There was a statistically significant difference between the CD62P expression of the two groups (p = 0.00). The group transfused with nonleucodepleted, and leucodepleted PCs showed respective median CCI of 18.8 x 109/L (2.4{\textendash}94.8 x 109/L) and 14.7 x 109/L (2.4{\textendash}124.0 x 109/L). There was no statistically significant difference between the CCI of the two groups (p = 0.42). It can be concluded that the CD62P expression in the PCs of the leucodepleted group was significantly lower than those of the nonleucodepleted group and that there was no significant difference between the CCI of both groups.

}, keywords = {CD62P, Corrected count increment, Platelet concentrates}, doi = {10.5530/pj.2023.15.33}, author = {Teguh Triyono and Zelly Dia Rofinda} } @article {1908, title = {Increased Risk of Tumor Necrosis Factor-Alpha Levels in Adult Patients with Malignancy Receiving Non-Leucodepleted Packed Red Cells Transfusion}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {December 2022}, pages = {778-781}, type = {Original Article }, chapter = {778}, abstract = {

Background and Objectives: Blood transfusion in patients with malignancy may evoke transfusion reactions. Leukocyte, as a major producer of cytokines, including Tumor Necrosis Factor-alpha (TNF-alpha), is considered to correlate to transfusion reactions. This study aims to determine the risk of increased TNFalpha in adult patients with malignancy who received non-leucodepleted (nLD) erythrocyte transfusion compared to those receiving leucodepleted (LD) Packed Red Cells (PRC) transfusion. Materials and Methods: This quasi-experimental study was conducted on adult patients with malignancy who required PRC transfusion and underwent outpatient treatment. The patients were divided without randomization into nLD and LD groups, and then their pre-transfusion TNF-alpha levels and the post-transfusion changes were examined. Results: This study included thirty-one patients fulfilling the inclusion criteria. The TNFalpha levels in nLD and LD groups after transfusion increased significantly (p \< 0.05), i.e., from 0.81 (0.2 - 4.2) pg/mL and 1.7 (0.15 - 6.3) pg/mL to 10.1 (1.4 - 28.9) and 5.9 (0.95 - 12.9) pg/mL. There was no significant difference in the pre-transfusion median TNF-alpha levels between the nLD and LD groups (p = 0.122). However, the post-transfusion median TNF-alpha levels of the nLD group were significantly higher (p = 0.024). It indicated that the increase in TNF-alpha levels is associated with nLD blood products transfused. The Relative Risk of the increased TNF-alpha levels in nLD-PRC transfusion was 2.01 (95\% Confidence Interval: 1,153-3,502). Conclusion: nLD-PRC transfusion poses a 2.01 times risk for increased TNF-alpha levels compared to LD-PRC transfusion.

}, keywords = {Malignancy, Non-leucodepleted, PRC transfusion, Relative risk, TNF-Alpha}, doi = {10.5530/pj.2022.14.167}, author = {Teguh Triyono and Bambang Hendriawan Prasaja Jati and Usi Sukorini} }